DepYmed Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $250K

  • Investors
  • 7

DepYmed General Information

Description

Developer of potent inhibitors of the enzyme designed to offer therapeutics for cancer and rare diseases. The company develops novel small-molecule phosphatase inhibitors and copper-chelating compounds targeting protein tyrosine phosphatases, with applications across cancer, Wilson's Disease, Rett Syndrome, and other metabolic and rare disease indications, enabling pharmaceutical and biotechnology stakeholders to advance therapeutic candidates into clinical development.

Contact Information

Website
www.depymed.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3 Bioscience Park Drive
  • Farmingdale, NY 11735
  • United States
+1 (516)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • 3 Bioscience Park Drive
  • Farmingdale, NY 11735
  • United States
+1 (516)

DepYmed Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DepYmed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 10-Feb-2025 $250K Completed Pre-Clinical Trials
7. Later Stage VC 16-Aug-2024 Completed Pre-Clinical Trials
6. Later Stage VC 02-May-2023 Completed Pre-Clinical Trials
5. Later Stage VC (Series A) 07-Apr-2021 Completed Pre-Clinical Trials
4. Early Stage VC (Series A3) 28-Oct-2016 Completed Pre-Clinical Trials
3. Early Stage VC (Series A1) 30-Nov-2015 Completed Pre-Clinical Trials
2. Accelerator/Incubator 25-Mar-2015 $100K $100K Completed Startup
1. Joint Venture 01-Jan-2014 Completed Startup
To view DepYmed’s complete valuation and funding history, request access »

DepYmed Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-4
Series A-3
Series A-1 532,310 $0.000100 6% $1.06 $1.06 1x $1.06 3.3%
To view DepYmed’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

DepYmed Patents

DepYmed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019308311-A1 (pyridinylmethyl)butanediamine derivatives that chelate copper Active 20-Jul-2018
AU-2019308311-B2 (pyridinylmethyl)butanediamine derivatives that chelate copper Active 20-Jul-2018
CA-3110049-A1 (pyridinylmethyl)butanediamine derivatives that chelate copper Pending 20-Jul-2018
EP-3823977-A1 (pyridinylmethyl)butanediamine derivatives that chelate copper Active 20-Jul-2018
EP-3823977-A4 (pyridinylmethyl)butanediamine derivatives that chelate copper Active 20-Jul-2018 A61P1/16
To view DepYmed’s complete patent history, request access »

DepYmed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DepYmed Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Topspin Consumer Partners PE/Buyout Minority
Jove Equity Partners Venture Capital Minority
Accelerate Long Island Accelerator/Incubator Minority
Long Island Emerging Technologies Fund Venture Capital Minority
Cold Spring Harbor Laboratory Corporation Minority
You’re viewing 5 of 7 investors. Get the full list »

DepYmed FAQs

  • When was DepYmed founded?

    DepYmed was founded in 2014.

  • Where is DepYmed headquartered?

    DepYmed is headquartered in Farmingdale, NY.

  • What is the size of DepYmed?

    DepYmed has 2 total employees.

  • What industry is DepYmed in?

    DepYmed’s primary industry is Drug Discovery.

  • Is DepYmed a private or public company?

    DepYmed is a Private company.

  • What is DepYmed’s current revenue?

    The current revenue for DepYmed is .

  • How much funding has DepYmed raised over time?

    DepYmed has raised $14.3M.

  • Who are DepYmed’s investors?

    Topspin Consumer Partners, Jove Equity Partners, Accelerate Long Island, Long Island Emerging Technologies Fund, and Cold Spring Harbor Laboratory are 5 of 7 investors who have invested in DepYmed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process